Below are the most recent publications written about "Neoplasm Staging" by people in Profiles.
-
Shahwan KT, Walker TD, Tan A, Ruiz E, Ran N, Granger EE, Koyfman S, Vidimos A, Wysong A, Hirotsu KE, Carucci JA, Carter JB, Ca?ueto J, Girardi FM, Mangold AR, Srivastava D, Brodland DG, Zitelli JA, Willenbrink TJ, Carr DR. Identifying the impact of minor risk factors in Brigham and Women's Hospital stage T1 cutaneous squamous cell carcinomas on risk of poor outcomes: A retrospective cohort study. J Am Acad Dermatol. 2025 06; 92(6):1319-1326.
-
Gray T, Liu CW, Kolano AM, Donaghue J, Stephans K, Videtic G, Xia P, Farr J. Assessing proton plans with 3 different beam lines vs photon plans for early-stage lung cancer. Med Dosim. 2025 Autumn; 50(3):209-215.
-
Schilder RJ, Rasco D, Sharma MR. An open-label study to determine the maximum tolerated dose of oral ESK-440 administered as a single agent in patients with advanced or metastatic solid tumors. Neoplasia. 2025 03; 61:101133.
-
Gaillard S, Lacchetti C, Armstrong DK, Cliby WA, Edelson MI, Garcia AA, Ghebre RG, Gressel GM, Lesnock JL, Meyer LA, Moore KN, O'Cearbhaill RE, Olawaiye AB, Salani R, Sparacio D, van Driel WJ, Tew WP. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update. J Clin Oncol. 2025 03; 43(7):868-891.
-
Mayadev J, Zamarin D, Deng W, Lankes HA, Pesci G, Kim H, Chino JP, Banbury B, Sherry N, Sharon E, Ghamande SA, Ferguson C, Mell L, Holman L, Mathews C, O'Malley D, Olawaiye A, Hopp E, Leath C, Copeland L, Mannel R, O'Cearbhaill R, Aghajanian C, Schilder RJ. Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial. Nat Commun. 2025 Jan 09; 16(1):553.
-
Matei DE, Enserro DM, Randall ME, Mutch D, Small W, DiSilvestro PA, Spirtos NM, O'Malley DM, Cantuaria GH, Michelin D, Waggoner S, Shahin M, Guntupalli S, Lara O, Ueland FR, Warshal D, Bonebrake A, Tewari KS, Tan A, Powell MA, Walker JL, Santin AD, Kim JH, Miller DS. Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma. J Clin Oncol. 2025 03 20; 43(9):1055-1060.
-
Geynisman DM, Abbosh PH, Ross E, Zibelman MR, Ghatalia P, Anari F, Mark JR, Stamatakis L, Hoffman-Censits JH, Viterbo R, Greenberg RE, Churilla TM, Horwitz EM, Hallman MA, Smaldone MC, Uzzo R, Chen DYT, Kutikov A, Plimack ER. Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1). J Clin Oncol. 2025 03 20; 43(9):1113-1122.
-
Bhutiani N, Hu CY, Palis B, Cotler J, Shi Q, Washington MK, Goldberg RM, Steele SR, Chang GJ. Lack of Hierarchical Survival Prognosis in AJCC Staging for Colon and Rectal Cancer-Implications for Future Summary Stage Classification. Clin Colorectal Cancer. 2025 06; 24(2):159-165.e2.
-
Brown JC, Ma C, Shi Q, Couture F, Kuebler P, Kumar P, Tan B, Krishnamurthi S, Chang V, Goldberg RM, O'Reilly EM, Shields AF, Meyerhardt JA. Inflammation, physical activity, and disease-free survival in stage III colon cancer: Cancer and Leukemia Group B-Southwest Oncology Group 80702 (Alliance). J Natl Cancer Inst. 2024 12 01; 116(12):2032-2039.
-
Shore ND, Morgans AK, Tutrone RF. Testosterone recovery post discontinuation of androgen deprivation for the treatment of advanced prostate cancer. Future Oncol. 2024 Dec; 20(39):3179-3182.